List of Excipients in Branded Drug AMITZA

Generic Drugs Containing AMITZA

Company	Ingredient	NDC	Excipient
Direct_Rx	lubiprostone	72189-410	FERRIC OXIDE RED
Direct_Rx	lubiprostone	72189-410	FERROSOFERRIC OXIDE
Direct_Rx	lubiprostone	72189-410	GELATIN
Direct_Rx	lubiprostone	72189-410	HYPROMELLOSE
Direct_Rx	lubiprostone	72189-410	LECITHIN, SOYBEAN
Direct_Rx	lubiprostone	72189-410	MEDIUM-CHAIN TRIGLYCERIDES

What are the Most Frequently-Used Excipients in AMITZA?

# Of NDCs	Excipient
1	FERRIC OXIDE RED
1	FERROSOFERRIC OXIDE
1	GELATIN
1	HYPROMELLOSE
1	LECITHIN, SOYBEAN
1	MEDIUM-CHAIN TRIGLYCERIDES

AMITIZA Excipient Strategy and Commercial Opportunities for Lubiprostone

Last updated: August 4, 2026

AMITIZA is the branded lubiprostone product, an oral chloride-channel activator supplied as 8 mcg and 24 mcg softgel capsules. Its commercial position has weakened because generic lubiprostone is available, but opportunities remain in excipient sourcing, softgel manufacturing, differentiated formulations, pediatric delivery, supply-chain localization, and lifecycle management. The most attractive strategy is not simple excipient substitution. It is a controlled redesign of the low-dose, lipid-filled softgel platform that preserves dissolution, content uniformity, stability, and gastrointestinal tolerability.

Key commercial conclusions

• AMITIZA uses a low-dose lipid-filled softgel format that creates meaningful formulation and manufacturing barriers.
• The main excipient categories are gelatin, sorbitol, purified water, medium-chain triglycerides, lecithin and capsule colorants or opacifiers, subject to the applicable product label and market.
• Generic competition has reduced the value of the original brand, but excipient suppliers and contract manufacturers can still monetize approved-product supply.
• A differentiated lubiprostone product would need a clear advantage, such as easier administration, vegetarian capsule technology, pediatric dosing, improved stability, or lower manufacturing cost.
• Reformulation must address the drug's very low strength, oil-phase dispersion, capsule-shell compatibility and dissolution performance.
• The principal regulatory route for a generic is an ANDA. A materially different formulation or delivery system may require a 505(b)(2) application.

What is AMITIZA and how is lubiprostone formulated?

AMITIZA contains lubiprostone, a locally acting prostaglandin-derived compound approved in the United States for chronic idiopathic constipation, opioid-induced constipation in adults with chronic non-cancer pain, and irritable bowel syndrome with constipation in adult women [1].

Product attribute	AMITIZA position
Active ingredient	Lubiprostone
Strengths	8 mcg and 24 mcg
Dosage form	Oral softgel capsule
Main indications	CIC, OIC and IBS-C, subject to labeling limitations
Original sponsor	Sucampo Pharmaceuticals
Commercial partner	Takeda
FDA application	NDA 021908
Administration	Oral, generally twice daily depending on indication
Main formulation issue	Uniform delivery of a microgram-level dose in a lipid-filled capsule

Lubiprostone is administered at a very low dose compared with most oral solid-dose drugs. That creates a high ratio of excipient mass to active pharmaceutical ingredient. Small changes in blend homogeneity, oil viscosity, filling accuracy or capsule-shell behavior can materially affect dose uniformity.

The product is generally described in FDA labeling as a softgel formulation containing an oil vehicle and capsule-shell excipients. The exact inactive-ingredient composition should be verified against the current FDA labeling and the target-market product dossier before commercial development [1, 2].

What excipients are used in AMITIZA softgel capsules?

The formulation strategy has four functional layers: drug dispersion, lipid vehicle, capsule shell and visual or physical protection.

Excipient class	Likely function in the AMITIZA platform	Commercial relevance
Medium-chain triglycerides	Lipid vehicle and dispersion medium	High-volume, qualified lipid supply
Lecithin	Wetting, dispersion and interfacial stabilization	Potentially important for content uniformity
Gelatin	Softgel shell former	Major manufacturing and animal-origin consideration
Sorbitol	Plasticizer and shell-moisture modifier	Controls shell flexibility and brittleness
Purified water	Capsule-shell processing aid	Critical to shell moisture balance
Titanium dioxide or other opacifier	Appearance and light protection	Regulatory and market-specific scrutiny
Iron oxides or certified colorants	Strength identification	Low cost but important for product recognition
Packaging components	Moisture and oxygen protection	Relevant to stability and shelf life

The active ingredient is the highest-value formulation component, but the excipient system determines manufacturability. A softgel formulation must maintain a controlled balance between fill viscosity, shell elasticity, seam integrity, drying behavior and long-term moisture migration.

For a generic product, the safest commercial route is usually to retain the reference product's functional excipient architecture while qualifying alternate suppliers. A substantial change in vehicle, shell composition or dosage form can increase bioequivalence and chemistry, manufacturing and controls risk.

How does the softgel excipient strategy affect manufacturing?

Low-dose content uniformity

Lubiprostone is present at 8 mcg or 24 mcg per capsule. Direct filling of such a small drug quantity is difficult. The API must be dissolved, suspended or distributed in a larger liquid fill with validated mixing and sampling procedures.

The key controls are:

1. API particle-size and solid-state control.
2. Premixing or geometric dilution where applicable.
3. Agitation during filling.
4. Fill-weight accuracy.
5. In-process assay of the liquid fill.
6. Hold-time validation.
7. Control of API precipitation or sedimentation.

A formulation that uses a true solution may simplify content uniformity but can create solubility, crystallization or temperature-sensitivity risks. A suspension can increase physical stability challenges but may be more flexible for API loading.

Lipid vehicle selection

Medium-chain triglycerides are commercially attractive because they are widely available, chemically stable and commonly used in oral lipid formulations. They also support softgel processing at relatively manageable viscosities.

Potential alternatives include other pharmaceutical-grade triglyceride systems, but each change can alter:

• Lubiprostone solubility or dispersion.
• Fill viscosity.
• Capsule-seam performance.
• Dissolution in simulated gastrointestinal media.
• Oxidative stability.
• Interaction with lecithin or other surfactants.

A vehicle change is therefore more than an excipient sourcing exercise. It can become a formulation-development program requiring comparative dissolution and, depending on the extent of change, additional bioequivalence justification.

Gelatin-shell performance

Gelatin provides a mature and cost-efficient softgel shell platform. Its main disadvantages are animal origin, variability in bloom strength and potential restrictions in certain markets.

The shell must be compatible with the fill. Lipid migration, moisture exchange and shell plasticization can cause brittleness, tackiness, leakage or seam failure. Sorbitol concentration and shell-water content are especially important.

Vegetarian alternatives, including modified starch or hydroxypropyl methylcellulose systems, may expand market access but carry higher development risk. They can require different encapsulation equipment, drying conditions and sealing parameters.

What formulation patents protect AMITIZA and lubiprostone?

AMITIZA's historical intellectual-property position has included patents directed to lubiprostone compositions and therapeutic uses. Public patent records and FDA Orange Book data should be evaluated by product strength, indication and jurisdiction because the relevant claims may differ across patents and markets [2, 3].

The principal commercial IP categories are:

IP category	Relevance to AMITIZA
Lubiprostone composition patents	Protect the active compound or defined chemical forms
Pharmaceutical composition patents	May cover dosage forms, vehicles or concentration ranges
Method-of-use patents	Cover treatment of constipation or IBS-C populations
Manufacturing patents	May cover API preparation or formulation processes
Regulatory exclusivity	Depends on the original NDA and later supplements
Trademark rights	Protect AMITIZA branding rather than formulation chemistry

The original composition and use patent estate has provided protection into the 2020s, with some historical U.S. patent rights extending toward 2027. Generic launch decisions depend on the specific Orange Book listing, Paragraph IV certifications, patent-term adjustments, pediatric extensions and settlement terms.

A formulation patent covering a specific softgel shell or lipid vehicle would be commercially valuable only if the claims are narrow enough to survive validity challenges and broad enough to capture competing products. Excipient patents are often vulnerable when they claim routine substitutions without unexpected performance data.

When does AMITIZA lose exclusivity and what is the generic-entry position?

AMITIZA's market exclusivity has already been materially reduced by generic lubiprostone approvals. FDA generic approval depends on demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug, together with compliance with applicable patent certifications [2].

Exclusivity component	Commercial effect
Original NDA exclusivity	Protected initial branded entry and indication expansion
Listed patents	Could delay or condition ANDA launch
Paragraph IV certification	Creates possible patent litigation and 30-month stay risk
Generic approval	Reduces price and share for the branded product
Authorized generic	Can preserve some manufacturer economics
505(b)(2) reformulation	May support differentiated labeling or delivery

The presence of generic products changes the opportunity set. A new entrant no longer needs to compete only against the branded softgel. It must also compete against generic lubiprostone on price, supply reliability and payer substitution.

For an excipient supplier, the commercial target is therefore broader than Takeda. Generic manufacturers, contract softgel producers and regional licensees may require equivalent or alternate pharmaceutical-grade ingredients.

Which companies are challenging AMITIZA commercially?

The principal competitive pressure comes from generic manufacturers that have obtained or pursued FDA approval for lubiprostone capsules. The market may include products from large generic companies, specialty pharmaceutical firms and contract-manufactured suppliers, depending on the jurisdiction and launch status.

The competitive landscape includes:

• Takeda's branded AMITIZA.
• FDA-approved generic lubiprostone capsule manufacturers.
• Authorized or contract-manufactured versions.
• Alternative constipation products, including linaclotide, plecanatide, prucalopride, polyethylene glycol and stimulant or osmotic laxatives.
• New delivery systems targeting pediatric, geriatric or dysphagia populations.

Generic competition is strongest in chronic idiopathic constipation and opioid-induced constipation, where prescribers can substitute across several established therapies. IBS-C creates a more differentiated opportunity because tolerability, diarrhea risk, dosing convenience and payer coverage influence product choice.

What excipient opportunities exist for AMITIZA and generic lubiprostone?

1. Qualified alternate suppliers

The lowest-risk opportunity is dual sourcing of existing excipients. Potential targets include:

• Pharmaceutical-grade medium-chain triglycerides.
• Gelatin with controlled bloom strength.
• Sorbitol with low bioburden and consistent moisture.
• Lecithin with controlled phospholipid profile.
• Colorants and opacifiers with global regulatory support.
• Moisture-barrier blister and bottle packaging.

Alternate suppliers can win business through lower cost, regional manufacturing, improved supply continuity or documentation quality. The qualification burden is lower when the replacement meets the same compendial and functional specifications.

2. Vegetarian or non-animal softgel systems

A gelatin-free lubiprostone softgel could address religious, ethical and geographic market requirements. The opportunity is commercially meaningful but technically harder than conventional supplier substitution.

Development priorities would include:

• Shell elasticity.
• Seam strength.
• Fill-shell compatibility.
• Drying time.
• Moisture migration.
• Long-term stability.
• Comparable dissolution.
• Patient acceptability.

A gelatin-free product may support a 505(b)(2) strategy if it differs materially from the reference product.

3. Pediatric and dysphagia-friendly dosage forms

The existing capsule format limits use in patients who cannot swallow softgels. Potential products include:

• Unit-dose oral liquid.
• Liquid-filled sachet.
• Sprinkle-compatible capsule.
• Smaller capsule size.
• Orodispersible or dispersible dosage form.
• Caregiver-administered suspension.

These products would need to demonstrate dose accuracy, chemical stability and appropriate administration instructions. Lubiprostone's low dose makes unit-dose liquids technically feasible, but adsorption to containers, preservative selection and dose measurement become central development issues.

4. Stability-enhancing lipid systems

A redesigned lipid vehicle could improve shelf life or reduce manufacturing cost. The most credible opportunities involve controlling:

• Oxidation.
• API precipitation.
• Fill viscosity.
• Capsule leakage.
• Light sensitivity.
• Temperature excursions during distribution.

Antioxidants, chelators or alternate lipid grades may be useful, but they introduce new safety and regulatory assessments. The development case must show a measurable benefit, not only a different excipient list.

5. Regional manufacturing and supply-chain localization

Softgel production is concentrated among specialized manufacturers. Regional capacity can create value where companies need:

• Reduced dependence on a single site.
• Shorter lead times.
• Local regulatory compliance.
• Lower freight and inventory costs.
• Backup production after quality events.
• Access to markets with local-content requirements.

A supplier with integrated API, fill formulation, encapsulation, drying, inspection and packaging can capture more margin than an excipient-only vendor.

How strong is the formulation IP opportunity?

The strongest IP opportunity is a formulation that solves a defined technical or commercial problem and produces measurable performance data. Examples include:

• A non-gelatin shell with equivalent or superior stability.
• A lipid system that prevents API crystallization.
• A pediatric liquid with extended in-use stability.
• A capsule that improves dose uniformity at 8 mcg.
• A packaging system that extends shelf life under high humidity.
• A manufacturing process that reduces fill-weight variability.

Weak patent candidates include routine substitutions of one pharmacopeial-grade oil for another, colorant changes, or conventional gelatin-plasticizer adjustments without unexpected results.

A strong patent position would combine composition claims, process claims and method-of-use claims. Geographic coverage should prioritize the United States, European Union, Japan, China, Canada, Australia and major emerging markets where chronic constipation therapies have meaningful demand.

What regulatory path applies to a new AMITIZA formulation?

Product concept	Likely FDA pathway
Same strength, dosage form and route with equivalent excipients	ANDA
Different excipient system with same active and route	ANDA or 505(b)(2), depending on sameness and evidence
New liquid or pediatric dosage form	Usually 505(b)(2)
New indication	Supplemental NDA or 505(b)(2)
Novel combination product	505(b)(2) or NDA
Foreign-market equivalent	Local generic or hybrid application

The FDA may accept inactive-ingredient differences in an ANDA if the product remains pharmaceutically equivalent and bioequivalent and the differences comply with regulatory requirements. A major change to the dosage form, release profile, route, labeling or clinical use can move the product outside the conventional ANDA pathway [4].

Excipient selection must also account for the FDA Inactive Ingredient Database, maximum potency exposure, route-specific precedent and pediatric acceptability [5]. Capsule colorants, titanium dioxide, animal-derived gelatin and allergens may create market-specific issues even when they do not block U.S. approval.

What commercial risks affect an AMITIZA excipient strategy?

The main risks are:

1. Generic price erosion limits the value of premium formulation changes.
2. A new softgel shell may require substantial process redevelopment.
3. Excipient changes can alter dissolution and trigger additional bioequivalence work.
4. Low API loading magnifies small manufacturing deviations.
5. Gelatin and sorbitol supply interruptions can stop production.
6. Global colorant and titanium dioxide rules may require multiple regional formulations.
7. A 505(b)(2) product may face patent litigation or labeling restrictions.
8. Competing constipation products may reduce achievable pricing.
9. Payers may treat a differentiated lubiprostone product as interchangeable with low-cost generics.
10. Patent claims directed only to routine excipient substitutions may have limited enforceability.

What is the best commercial strategy for lubiprostone excipients?

The highest-probability strategy is a staged model:

Stage	Objective	Risk
1	Qualify alternate lipid, shell and plasticizer suppliers	Low
2	Offer regional softgel manufacturing and packaging	Moderate
3	Develop a gelatin-free or pediatric presentation	Moderate to high
4	File formulation and process patents	High
5	Launch through ANDA or 505(b)(2) pathway	Regulatory and commercial

A supplier seeking near-term revenue should prioritize qualified materials and contract manufacturing. A specialty pharmaceutical company seeking higher margins should pursue a differentiated dosage form, particularly a pediatric or dysphagia-friendly product. A new branded product needs a clinical or usability benefit that supports pricing above generic lubiprostone.

Key Takeaways

• AMITIZA is a low-dose lubiprostone softgel with a formulation centered on a lipid fill and gelatin-based shell.
• The main excipient opportunities are alternate sourcing, softgel manufacturing, gelatin-free shells, pediatric delivery and stability improvement.
• Generic competition means cost, reliability and regulatory execution are more important than simple product imitation.
• A materially different formulation may require a 505(b)(2) application rather than an ANDA.
• The strongest IP position will protect a demonstrated technical improvement, not a routine excipient substitution.
• The most practical near-term opportunity is supply-chain and manufacturing participation in generic lubiprostone.
• The most valuable longer-term opportunity is a differentiated dosage form that improves administration or expands the patient population.

FAQs

Can medium-chain triglycerides in AMITIZA be replaced?

Yes, but replacement requires evaluation of lubiprostone solubility or dispersion, viscosity, dissolution, stability and capsule compatibility. A replacement that is pharmaceutically equivalent may support an ANDA strategy; a materially different vehicle may require a 505(b)(2) approach.

Is a gelatin-free AMITIZA capsule commercially viable?

Yes, but it would need to match the performance of the reference softgel while addressing shell elasticity, sealing, drying, moisture migration and stability. Its strongest commercial rationale would be market access, dietary requirements or a premium differentiated product.

Does AMITIZA have a meaningful excipient patent opportunity?

The opportunity is selective. Patents are more defensible when they cover a specific shell, lipid system or process that produces unexpected stability, dissolution or manufacturing results.

Can lubiprostone be developed as an oral liquid?

Potentially. The principal development issues would be API solubility or uniform dispersion, preservative compatibility, container adsorption, dose measurement, in-use stability and taste or mouthfeel.

Which excipient category has the greatest supply-chain value?

Medium-chain triglycerides and softgel-shell materials are the strongest near-term categories because they affect both formulation performance and manufacturing continuity. Gelatin-free shell systems offer greater differentiation but carry higher technical risk.

References

1. U.S. Food and Drug Administration. (2023). AMITIZA (lubiprostone) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for lubiprostone-related patents.
4. U.S. Food and Drug Administration. (2022). Approved drug products and abbreviated new drug application requirements under the Federal Food, Drug, and Cosmetic Act.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.